Peptide library › Infections
Murepavadin
Also known as POL7080
Experimental antibiotic designed to target Pseudomonas, the main lung infection in cystic fibrosis.
What people use it for
- Pseudomonas infections (in trials)
What Murepavadin does in the body
A ring-shaped peptide modelled on protegrin, a natural antimicrobial peptide. It blocks LptD, a protein Pseudomonas needs to build its outer membrane.
Strength of evidence
Limited: IV Phase 3 trials were stopped in 2019 because of kidney toxicity; an inhaled version is being developed.
Look up the evidence
- Reviews on PubMed: Summaries of the published research
- Clinical trials on PubMed: Published studies in people
- ClinicalTrials.gov: Registered trials, past and ongoing
Live searches of official databases. New to the terms? See the glossary.
Reported side effects & risks
- Kidney injury (IV form)
- Long-term safety unknown
Who should avoid it or take extra care
- Not available outside research
Not a complete list. Check with a doctor or pharmacist about your own health and medicines.
Regulatory status
Investigational. Not approved by the FDA.
How it's taken
Route: Drip into a vein (halted) or inhaled (in development)
How long it lasts (half-life): Not well established in published data
Keep track of Murepavadin privately
Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.
Open Murepavadin in Fiala How to installMore in Infections
- BacitracinPeptide antibiotic in over-the-counter ointments for minor cuts and grazes.
- Dalbavancin, oritavancin and telavancinLong-acting hospital antibiotics related to vancomycin, used for serious skin infections including MRSA.
- DaptomycinHospital antibiotic for serious skin and bloodstream infections, including MRSA.
- EchinocandinsFamily of hospital antifungal drugs for serious yeast and mould infections.
- Polymyxin B and colistinOld peptide antibiotics now kept as a last resort for multidrug-resistant gram-negative infections.
- VancomycinLong-established hospital antibiotic for MRSA and other serious infections; taken by mouth for C. difficile.
- EnfuvirtideFirst HIV fusion inhibitor, a twice-daily injection for resistant HIV; discontinued in the US in 2025.
- BrilacidinExperimental drug that mimics the body's own antimicrobial defensins, studied for infections and inflammation.